Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (July 2022)
44 slides from Inhibrx Biosciences's investor presentation, July 2022
Slide 1: Innovation Driven, Outcomes Focused
Innovation Driven Outcomes Focused July 2022
Slide 2: Presentation disclaimer
Presentation disclaimer Commission filings, including those described in our Annual Report on Form 10-K as This presentation contains forward-looking statements. In some cases, you can identify well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by forward-looking statemen
Slide 3: Four differentiated clinical programs
Four differentiated clinical programs Rare diseases Oncology Cell death pathway Immuno-oncology INBRX-101 INBRX-109 INBRX-106 INBRX-105 AAT-Fc fusion protein Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1 x 4-1BB tetravalent + Potential for first meaningful + Potential path to approval in + D
Slide 4: Why invest in Inhibrx?
Why invest in Inhibrx? KEY FINANCIAL HIGHLIGHTS* $176M Cash Four differentiated clinical Potential to reach programs with potentially value- financial sustainability creating readouts in 2022/2023 with minimal dilution $30+M Average per Qtr burn rate 39.0M Common stock outstanding Backed by solid in
Slide 5: Inhibrx at a glance
Inhibrx at a glance PARTNERSHIPS WITH INDUSTRY LEADERS + Experienced leadership team All platforms and programs + Proven innovation and execution developed in-house with strong patent protection + Ability to precision engineer to specific target biology + Smaller than conventional antibodies + Antib
Slide 6: INBRX-101
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 7: Functional AAT levels in healthy individuals vs. AATD patients
Functional AAT levels in healthy individuals vs. AATD patients 80 Disease history + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan 60 respiratory disease characterized by deficient levels of alpha-1 Functional AAT levels (μM) antitrypsin (AAT) + This causes loss of lung function and de
Slide 8: Current standard of care does not maintain normal AAT levels
Current standard of care does not maintain normal AAT levels + INBRX-101 dosed every four weeks at 120 Functional AAT serum levels at steady-state (INBRX-101 vs. pdAAT) mg/kg is predicted to maintain patients above the lower threshold of the normal range and 80 achieve an average level (Cavg) of fun
Slide 9: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101
Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential to extend the dosing interval from weekly to monthly AAT Has demonstrated potential to maintain patients in normal functional AAT range Fc Recombinant manufacturing provides abundant supply with no pathogen risk 9
Slide 10: INBRX-101 Topline results from Phase 1, Part 2
INBRX-101 - Topline results from Phase 1, Part 2 PART 2 INBRX-101 Topline Results - 40, 80 or 120 mg/kg(Q3W) Multiple ascending 100 dose escalation (MAD) 120 mg/kg 80 mg/kg Functional AAT levels (μM) 75 N=18 40 mg/kg N=6 40 mg/kg 50 N=6 80 mg/kg* Complete 25 N=6 120 mg/kg* Ongoing 0 0 21 42 63 * bro
Slide 11: INBRX-101 Results from Phase 1, Part 1
INBRX-101 - Results from Phase 1, Part 1 PART 1 Key functional AAT levels by dose Single ascending dose escalation (SAD) 80 Complete N=24 60 Functional AAT levels (μM) N=6 10 mg/kg Baseline AAT N=6 40 mg/kg Max AAT 40 Day 21 AAT N=6 80 mg/kg N=6 120 mg/kg 20 0 + Favorable safety and tolerability pro
Slide 12: INBRX-101 potential ~$3B annual U.S. revenue
INBRX-101 has the potential to achieve ~$3B in annual U.S. revenue with expected rapid uptake in patients with severe AATD INBRX-101 top line projected U.S. sales & key assumptions $3.0B KEY ASSUMPTIONS $3B + “Severe (ZZ/SZ)” AATD patients (same as pdAATs today) + 7% CAGR throughout forecast period
Slide 13: INBRX-101 potential to shift the treatment paradigm in AATD
INBRX-101 has the potential to shift the treatment paradigm, expanding augmentation therapy to a broad group of AATD patients in the U.S. TODAY FUTURE PI*ZZ or PI*SZ PI*ZZ or PI*SZ PI*MZ* U.S. prevalence ~100K ~100K (same as today) ~5-12M ~40% (driven by increased Treatment rate ~8-10% diagnosis rat
Slide 14: INBRX-109
INBRX-109 Tetravalent DR5 Agonist
Slide 15: Tetravalent DR5 agonist
Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor DR5: sdAb DR5: sdAb for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells Fc: effector function disabled 105 kDa 15
Slide 16: INBRX-109 is a best-in-class DR5 agonist
INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) INBRX-109 Tetravalent 105 TAS-2661 Tetravalent 60 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 GEN10291,2 Dodecavalent 150 ka (2x mAbs) IGM-8444 Decavalent3 ~950 Dulanermin (recombinant TRAIL) Trivalent 150 Tigatuzumab LBY-
Slide 17: Preliminary Phase 1 data in conventional chondrosarcoma
Preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma Best Response 3mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD (+7%) PD (+31
Slide 18: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma
INBRX-109 Phase 2 potentially registration-enabling study design in chondrosarcoma ENDPOINTS Randomization INBRX-109 Placebo Primary: Progression free Conventional chondrosarcoma, Grades Initiated survival 1, 2 and 3, unresectable or metastatic N=134* N=67 * Secondary: Overall survival, quality of l
Slide 19: Annual prevalent chondrosarcoma patient pool of ~2.5K in the U.S.
Many patients with local disease eventually progress to unresectable or metastatic chondrosarcoma, providing an annual prevalent patient pool of ~2.5K in the U.S. Conventional chondrosarcoma patient flow Unresectable or metastatic population (opportunity at launch) Legend: Peri-operative opportunity
Slide 20: INBRX-109 potential ~$1B annual revenue
Based on current trends and lack of approved options, INBRX-109 has the potential to achieve ~$1B in annual revenue with rapid uptake post launch INBRX-109 top line projected U.S. sales in the unresectable/metastatic setting & key assumptions $1.0B $1B KEY ASSUMPTIONS + ~375K* annual price per patie
Slide 21: Phase 1 single agent data in malignant pleural mesothelioma
Phase 1 single agent data in malignant pleural mesothelioma, epithelioid subtype PARTs 1 & 2 Best response 3mo 6mo 9mo SD (-24%) * SD (-17%) PART 3 SD (-12%) Combination PR (-100%) study SD (-22%) SD (-20%) N=10 Mesothelioma with SD (-12%) Cisplatin or SD (-5%) Carboplatin SD (-2%) N=10 Mesothelioma
Slide 22: INBRX-109 on the horizon
INBRX-109 on the horizon POTENTIAL FUTURE PART 3 OPPORTUNITIES Combination studies Solid tumors Pancreatic adenocarcinoma + IAP antagonists N=20 2nd line with mFOLFIRI Ongoing Hematologic tumors Ewing sarcoma with + Bcl-2 inhibitors N=20 Irinotecan + Temozolomide Ongoing NSCLC Colorectal Cancer with
Slide 23: INBRX-106
INBRX-106 Hexavalent OX40 Agonist
Slide 24: Hexavalent OX40 agonist
Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T-cells designed to: OX40: sdAb OX40: sdAb + Provide co-stimulation to activated T-cells + Reverse regulatory T-cell induced OX40: sdAb OX40: sdAb immune suppression + Enhance T-cell functionality Fc + Provi
Slide 25: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) Bivalent anti- INBRX-106 OX40 Hexavalent MOXR-0916 Discontinued GSK-3174998 Discontinued OX40 OX40 BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (H
Slide 26: INBRX-106 Phase 1 in combination with Keytruda
INBRX-106 Phase 1 in combination with Keytruda™ PART 3 PART 4 Dose Dose escalation expansion Complete Ongoing N=30 N=80 No pre-screening, all-comers CPI refractory CPI naive PD-L1+ cutaneous N=20 PD-L1+ NSCLC N=10 melanoma N=20 PD-L1+ basket N=10 PD-L1+ uveal melanoma N=10 PD-L1+ head & neck + Examp
Slide 27: INBRX-106 Phase 1 preliminary single agent activity
INBRX-106 Phase 1 preliminary single agent activity PART 1 PART 2 Dose escalation Dose expansion Complete Complete N=20 N=24 Patients were all-comers 0.03 mg/kg in two different dosing schedules in patients with tumor types responsive to CPIs + 4/10 response evaluable NSCLC & melanoma patients with
Slide 28: Market opportunity for INBRX-106 and INBRX-105
Market opportunity for INBRX-106 and INBRX-105 PD-1/PD-L1 WW Revenue PD-1/PD-L1 WW Revenue by Indication (in $ billions) (in $ billions) $70 $63.5 NSCLC 2020 2020 Projected 2026 $60 Melanoma Renal cell $50 carcinoma Bladder cancer $40 Head & neck cancers $30 $27.1 $28.2 Gastrointestinal adenocarcino
Slide 29: INBRX-105
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 30: PD-L1 x 4-1BB multispecific
PD-L1 x 4-1BB multispecific PD-L1: sdAb PD-L1: sdAb + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive
Slide 31: INBRX-105 is a potential best-in-class 4-1BB agonist
INBRX-105 is a potential best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/
Slide 32: INBRX-105 Phase 1 trial design
INBRX-105 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Complete Ongoing Complete Initiated Single agent dose escalation Single agent dose expansion Dose escalation with Keytruda™ Dose expansion with Keytruda™ N=32 N=38 N=30 N=105-175 No pre-screening, all-comers Single agent: PD-L1+ basket No pr
Slide 33: Molecular Targeted Cytokine (MTC) Platform
Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform
Slide 34: Affinity differential enables directed IL-2 expansion
Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity sdAb sdAb High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors Fc – effector function + Inh
Slide 35: INBRX-121
INBRX-121 NKp46 Targeted Detuned IL-2
Slide 36: INBRX-121 expanded the NK cell population and enhanced cytotoxicity
INBRX-121 expanded the NK cell population and enhanced cytotoxicity NKp46 sdAb NKp46 sdAb + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells Fc – effector function + Proprietary IL2-X engineering disabled ensures specific modulation of NK Cells without impacting
Slide 37: INBRX-121 poised to bring NK cells to the forefront of immunotherapy
INBRX-121 is poised to bring NK cells to the forefront of immunotherapy Improved NK Activity Safety with durability Multiple potential paths forward INBRX-121 NK NK Single agent NK NK Activated NK cells NK NK CYTOKINES exhibit immediate NK NK NK cytotoxicity NK INBRX-121 Combination therapy ⁺ Expand
Slide 38: Expanded mouse NK cells and enhanced their cytotoxic potential
Expanded mouse NK cells and enhanced their cytotoxic potential NK cell expansion NK cell activation NK cell cytolytic activity 25 5,000 20,000 Max. fold-change (relative to vehicle) 20 4,000 15,000 Granzyme B levels 15 3,000 KLRG1 levels 10,000 10 2,000 5,000 5 1,000 0 0 0 NK cells CD8 T cells Tregs
Slide 39: Synergized with approved therapeutic antibodies
Synergized with approved therapeutic antibodies Raji tumor growth 2,000 Vehicle 1,500 INBRX-121 Tumor Volume (mm3) 1,000 Rituxan INBRX-121 synergized with Rituxan® INBRX-121 + Rituxan in a subcutaneous 500 Raji tumor model resulting in complete 0 tumor regression 0 7 14 21 28 35 42 Dosing Time (days
Slide 40: INBRX-121 safely expanded NK cells in non-human primates
INBRX-121 safely expanded NK cells in non-human primates NK cell expansion in blood after NK Expanded NK cells a single dose of INBRX-121 at 1 mg/kg: NK in a dose-dependent NK NK manner (up to 12-fold) Frequency of lymphocytes NK NK NK NK that persists for more than Pre-dose Day 10 NK 21 days and ca
Slide 41: Expanded NK cells from lymphoma patients
Expanded NK cells from Lymphoma patients IL-2 signaling in patient NK cells Patient NK cell proliferation 60 60 % pSTAT5 positive 40 40 % Ki67 positive 20 20 0 0 INBRX-121 - + - + - + - + INBRX-121 - + - + - + - + DLBCL MCL FL Healthy DLBCL MCL FL Healthy Donor Donor NK cells from Lymphoma patients
Slide 42: Expanded NK cell number while enhancing cytotoxic capacities
Expanded the number of NK cells while enhancing their individual cytotoxic capacities 120 100 80 %Target celldeath Anti-hCD20-hlgG1 only INBRX-121 increased NK 60 Anti-hCD20-hlgG1 + cell-mediated killing of 40 INBRX-121 Raji cells in the presence of a Rituximab sequence 20 analog (Anti-hCD20- hIgG1)
Slide 43: Near term expected clinical milestones
Near term expected clinical milestones INBRX-109 INBRX-101 (DR5) Initial IDH mutant (AAT) Potential INBRX-106 INBRX-105 data at CTOS start to (OX40) / registration (PD-L1 x 41BB) Keytruda dose INBRX-101 Keytruda study expansion cohort data initial dose Registration expansion study guidance INBRX-121
Slide 44: 11025 N. Torrey Pines Rd, La Jolla, CA
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com